Quintiles Appoints New Executives
Quintiles Transnational Corp. names Senior Vice President, Global Marketing and Chief Marketing Officer and Senior Vice President, Communications and Patient Recruitment.
Quintiles Appoints New Executives
RESEARCH TRIANGLE PARK, N.C., June 19 /PRNewswire/ -- Quintiles Transnational Corp. today named Millie Tan to Senior Vice President, Global Marketing and Chief Marketing Officer and David Coman to the position of Senior Vice President, Communications and Patient Recruitment.
"Both Dave and Millie bring a wealth of experience and impressive records of success in marketing and communication," said Mike Mortimer, Chief Administrative Officer. "I am excited to have them join our senior management team to play key roles in our efforts to strengthen our presence in the marketplace."
Millie joins Quintiles from Monster Worldwide, the global online employment solutions provider, monster.com . Most recently, she was Chief Marketing Officer of its European business, prior to which, she led core marketing in the US. Previously, Millie held increasingly senior positions in consumer marketing with Polaroid and Gillette, including overseas assignments in Hong Kong and Tokyo. She earned her bachelor's degree from Skidmore College in Saratoga Springs, NY, and her master's degree at Columbia University, followed by an MBA at Dartmouth College.
David joins Quintiles from Dendrite International where he was the VP of Global Marketing and led both Marketing and Corporate Communications. Previously, David held executive leadership positions in high-growth telecommunications companies where he initiated groundbreaking
direct-to-consumer strategies. He began his career with Young & Rubicam, a
market-leading global advertising agency. He earned his bachelor's degree at Michigan State and his MBA from Northwestern University.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.quintiles.com .
SOURCE Quintiles Transnational Corp.
-0- 06/19/2008
/CONTACT: Mari Mansfield, Media Relations of Quintiles Transnational Corp., +1-919-998-2639, +1-919-259-3298 (mobile), [email protected]/
/Web site: http://www.quintiles.com
http://www.qtrn.com /
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
